Reductions in blood pressure and lipid parameters are generally lower than those previously projected , though substantial heterogeneity of results exists .
Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo , single drug active component , or usual care but may be associated with improved adherence to a multidrug regimen .
BACKGROUND Cardiovascular disease ( CVD ) is the leading cause of death and disability worldwide , yet CVD risk factor control and secondary prevention rates remain low .
A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill , or polypill , has been proposed as one strategy to reduce the global burden of CVD by up to 80 % given its potential for better adherence and lower costs .
OBJECTIVES To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD .
We also aim ed to determine discontinuation rates , adverse events , health-related quality of life , and costs of fixed-dose combination therapy .
Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.
This 8-week , r and omized , double-blind , controlled study compared efficacy and tolerability of telmisartan/amlodipine ( T/A ) single-pill combination ( SPC ) vs the respective monotherapies in 858 patients with severe hypertension ( systolic/diastolic blood pressure [ SBP/DBP ] ≥180/95 mm Hg ) . At 8 weeks , T/A provided significantly greater reductions from baseline in seated trough cuff SBP/DBP ( -47.5 mm Hg/-18.7 mm Hg ) vs T ( P<.0001 ) or A ( P=.0002 ) monotherapy ; superior reductions were also evident at 1 , 2 , 4 , and 6 weeks . Blood pressure ( BP ) goal and response rates were consistently higher with T/A vs T or A. T/A was well tolerated , with less frequent treatment-related adverse events vs A ( 12.6 % vs 16.4 % ) and a numerically lower incidence of peripheral edema and treatment discontinuation . In conclusion , treatment of patients with substantially elevated BP  with T/A SPCs result ed in high and significantly greater BP reductions and higher BP goal and response rates than the respective monotherapies . T/A SPCs were well tolerated
Reductions in blood pressure and lipid parameters are generally lower than those previously projected , though substantial heterogeneity of results exists .
Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo , single drug active component , or usual care but may be associated with improved adherence to a multidrug regimen .
BACKGROUND Cardiovascular disease ( CVD ) is the leading cause of death and disability worldwide , yet CVD risk factor control and secondary prevention rates remain low .
A fixed-dose combination of blood pressure and cholesterol lowering and antiplatelet treatments into a single pill , or polypill , has been proposed as one strategy to reduce the global burden of CVD by up to 80 % given its potential for better adherence and lower costs .
OBJECTIVES To determine the effectiveness of fixed-dose combination therapy on reducing fatal and non-fatal CVD events and on improving blood pressure and lipid CVD risk factors for both primary and secondary prevention of CVD .
We also aim ed to determine discontinuation rates , adverse events , health-related quality of life , and costs of fixed-dose combination therapy .